

1.121(b)(1)(iii), applicants submit a marked up version of replacement paragraphs. Applicants have also directed entry of the sequence listing into the specification.


**Requirements Under 37 C.F.R. 1.821-1.825**

Applicants have hereinabove directed entry of the paper copy of the sequence listing into the specification. Applicants also submit herewith a computer readable form (CRF) copy of the sequence listing as required by 37 C.F.R. 1.821(e). The attached CRF copy conforms to the requirements of 37 C.F.R. 1.824 and was prepared using the PatentIn 3.1 Program. The sequence listing information recorded in the CRF is identical to the written sequence listing. No new matter is introduced by entering the sequence listing into the application.

No additional fee is believed necessary for entry of this amendment. However, the Commissioner is hereby authorized to charge any fee or credit any overpayment to Deposit Account No. 50-0540.

Respectfully submitted,

KRAMER LEVIN NAFTALIS & FRANKEL LLP  
Attorneys for Applicants

By:   
Barry Evans, Esq.  
Reg. No. 22,802  
(212) 715-7609  
Robert E. Alderson, Jr.  
Reg. No. 44,500  
(212) 715-7697



PATENT  
116142-00170  
U.S. Patent Application  
Serial No. 09/898,616

**37 C.F.R. §§ 1.121(b)(1)(iii) MARKED UP VERSION  
OF REPLACEMENT PARAGRAPHS**

Sir:

Pursuant to 37 C.F.R. §§ 1.121 (b)(1)(iii), applicants hereby submit a marked up version of the replaced paragraphs from the specification and claims to show the changes made relative to the previous version of those paragraphs. The changes are indicated using strikethroughs for material to be deleted and bold/italics for material to be added. Note that brackets (deleted) and underline (added) were not used since those symbols already existed in the paragraphs being amended.

**IN THE SPECIFICATION:**

At the paragraph on page 17, line 17:

FIGURE 31 shows an amino acid sequence for rhUG (SEQ. ID NO. ~~10~~ **11**)

At the paragraph on page 54, lines 17-20:

N-terminal Sequence analysis. The sequence of the N-terminus was carried out using pulsed phase N-terminal sequencing on an Applied Biosystems (ABI) 477A automatic protein sequencer. The analysis was performed by M-Scan Inc. A sequence of Ala-Ala-Glu-Ile (**SEQ. ID NO. 10**) was confirmed for cGMP batches of rhUG with standard research lot rhUG/7 as a control.

At the paragraph on page 66, lines 8-16:

RhUG (*SEQ. ID NO. 11*) is a dimeric protein with a molecular weight of 16110 kilodaltons as calculated from the amino acid sequence and confirmed by electrospray mass spectroscopy. The protein is composed of two subunits bound to one another by two cystine bonds. Relative subunit molecular weight and the presence of the cystine bonds has been determined by SDS-PAGE under reducing and non-reducing conditions. The DNA sequence of the bacterial strain, CG12, was confirmed as was the amino acid sequence of the N-terminus of the protein by Edman degradation. The sequence of the N-terminus was Ala-Ala-Glu-Ile as predicted (*SEQ. ID NO. 10*). Cysteine is not readily detected by this method both due to the inherent chemistry and to the fact that the cysteine is involved in sulfur bonding.